ABSTRACT Porcine reproductive and respiratory syndrome virus (PRRSV) remains a major threat to global swine industry, yet the immune mechanisms underlying protective vaccination are incompletely understood. Here, we applied integrated single‐cell RNA sequencing and T cell receptor (TCR) profiling to characterize immune responses in a PRRSV vaccination–challenge model spanning complete, partial, and non‐protection outcomes. We identified distinct CD8+ T cell subsets that were selectively enriched in protected animals vaccinated with modified live vaccine (MLV) and marked by clonal expansion, strong cytotoxic transcriptional programs, and enhanced functional activity, which correlated with rapid control of viremia after challenge. In contrast, non‐protected animals accumulated dysfunctional CD8+ T cells expressing exhaustion‐associated markers such as CTLA4 despite partial cytotoxic signatures. Mechanistically, the protection‐associated responses were primarily driven by viral structural proteins (SP). Replacing the SP‐coding region of a heterologous strain reshaped the CD8+ T cell landscape from a mixed cytotoxic/exhausted profile toward a protective program, accompanied by improved clinical outcomes. Further, optimal CD8+ T cell activation required macrophages/monocytes‐derived innate signaling, including TLR4 and TLR8 pathways, and was enhanced by CD4+ T cell help. Together, our findings define protection‐associated CD8+ T cell states linked to viral control and provide insights for rational PRRSV vaccine design.
C. Kong, Siang Chen, Maolin Li et al.· Advancement of science· 0 citations
CSFV is a highly contagious disease threatening global pig production. Conventional live vaccines protect effectively but prevent serological differentiation between infected and vaccinated animals-undermining surveillance and eradication efforts. Therefore, it is crucial to develop a new generation of safe and effective vaccines. This study targeted the CSFV E2 glycoprotein, rationally optimized its amino acid sequence, expressed the recombinant protein at high yield in CHO cells, and demonstrated its immunogenicity and complete protection against virulent CSFV challenge. The E2 subunit vaccine was safe in piglets, with no inflammation, fever, or mortality during immunization. The E2 subunit vaccine induces high titers of CSFV-specific and neutralizing antibodies, and its immune protection efficacy is no less than that of commercially available vaccines. In the piglet challenge test, no CSFV was detected in oral, nasal, or rectal swabs or peripheral blood from immunized piglets. No CSFV was detected in the spleen, lymph nodes, or tonsils at autopsy. No CSFV-specific lesions were found on histopathology. All immunized piglets survived. These results demonstrate that piglets vaccinated with the E2 subunit vaccine were completely protected against lethal CSFV challenge. The successful development of a recombinant E2 subunit vaccine against CSFV represents a strategic advance toward sustainable control and eventual eradication of the disease.